Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
07/2003
07/01/2003CA2122338C Novel human cdc25 genes, encoded products and uses therefor
07/01/2003CA2089194C Steroid derivatives
06/2003
06/26/2003WO2003052414A1 Screening method
06/26/2003WO2003052138A2 Methods of detecting modification of genetic material
06/26/2003WO2003052124A2 Screening method for agents useful in treating diabetes
06/26/2003WO2003052103A1 Membrane-associated glutathione-nonspecific prostaglandin e synthase
06/26/2003WO2003052091A1 Growth factor modified protein matrices for tissue engineering
06/26/2003WO2003052089A1 Disruption of the glutathione s-transferase-omega-1 gene
06/26/2003WO2003051922A1 Process for the purification and/or isolation of biologically active granulocyte colony stimulating factor
06/26/2003WO2003051917A2 Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
06/26/2003WO2003051905A2 Taojiks as modifiers of the beta-catenin pathway and methods of use
06/26/2003WO2003051893A2 Improvements in pharmaceutical compositions
06/26/2003WO2003051890A1 Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides
06/26/2003WO2003051887A1 N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors
06/26/2003WO2003051886A1 Pyrazolopyridazine derivatives
06/26/2003WO2003051885A1 Nitrogen-containing heterocyclic compounds and use thereof
06/26/2003WO2003051884A1 Fused indole compound, process for producing the same, and use
06/26/2003WO2003051883A1 Indole derivative
06/26/2003WO2003051880A1 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
06/26/2003WO2003051878A1 Quinolinones as prostaglandin receptor ligands
06/26/2003WO2003051876A1 Pyrazolopyridine derivatives and medicinal use thereof
06/26/2003WO2003051874A1 Bicyclic n-arylamides
06/26/2003WO2003051872A1 Ethylene diamine derivatives and their use as orexin-receptor antagonists
06/26/2003WO2003051870A1 Novel compounds
06/26/2003WO2003051869A1 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives
06/26/2003WO2003051868A1 Lactams as tachykinin antagonists
06/26/2003WO2003051851A1 5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists
06/26/2003WO2003051844A1 2,3-dihydro-1h-quinolin-4-one oxime derivative and inhibitors of the induction of heat shock protein expression
06/26/2003WO2003051842A2 Compositions decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051841A2 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
06/26/2003WO2003051838A2 Protein kinase inhibitors
06/26/2003WO2003051837A2 Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr)
06/26/2003WO2003051836A1 Prodrugs to d-prolines
06/26/2003WO2003051833A2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
06/26/2003WO2003051831A2 Protease inhibitors of the coagulation cascade isolated from dysidea sponges
06/26/2003WO2003051825A1 Human adam-10 inhibitors
06/26/2003WO2003051822A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003WO2003051821A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar)
06/26/2003WO2003051807A2 Improvements in pharmaceutical compositions
06/26/2003WO2003051804A1 Novel substance having antitumor/anti-inflammatory activity
06/26/2003WO2003051400A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003WO2003051387A1 Remedies and/or preventives for conformational diseases
06/26/2003WO2003051383A2 Use of hmgb proteins and nucleic acids that code therefor
06/26/2003WO2003051382A1 Method of inducing apoptosis and compositions therefor
06/26/2003WO2003051380A2 Compositions containeing curcuma extracts for the treatment of neurocerebrovascular disorders
06/26/2003WO2003051371A1 Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
06/26/2003WO2003051370A1 Selective dopamine d3 receptor agonists for the treatment of sexual dysfunction
06/26/2003WO2003051361A1 Use of hiv-1 protease inhibitors and their derivatives in the treatment of inflammation
06/26/2003WO2003051360A1 Cis-imidazolines as mdm2 inhibitors
06/26/2003WO2003051359A1 Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
06/26/2003WO2003051358A1 Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
06/26/2003WO2003051356A1 Method for treating circadian rhythm disruptions
06/26/2003WO2003051350A1 Use of lipoxin analogs to promote cell defense against gram-negative infections
06/26/2003WO2003051344A1 Methods of inducing ovulation_using a non-polypeptide camp level modulator
06/26/2003WO2003051333A1 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents
06/26/2003WO2003051313A2 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
06/26/2003WO2003051306A2 N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections
06/26/2003WO2003051302A2 Methods and compositions for treatment of central nervous system disorders
06/26/2003WO2003051289A2 Solubilized topoisomerase poison agents
06/26/2003WO2003051287A2 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003WO2003051278A2 Nanoparticle delivery vehicle
06/26/2003WO2003051277A2 Novel compounds
06/26/2003WO2003040109A3 Quinazoline derivatives as antitumor agents
06/26/2003WO2002098352A3 PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
06/26/2003WO2002094202A3 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
06/26/2003WO2002060340A3 Method for identifying maxi-k channel blockers
06/26/2003WO2002058733A3 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
06/26/2003WO2002044406A3 Projection against mycobacterial infections
06/26/2003WO2002018608A3 Methods for enhancing the efficacy of cancer therapy
06/26/2003US20030121065 Polyfunctional base sequence and artificial gene containing the same
06/26/2003US20030120093 Reacting cytotoxic hydrofuranoxanthones with palladium complex and benzoquinone in presence of dimethyl sulfoxide; antiproliferative/antitumor agents; topoisomerase inhibitors; downregulating oncogenes
06/26/2003US20030120081 Process for the preparation of non-steroidal glucocorticoid receptor modulators
06/26/2003US20030120074 Cardioprotective phosphonates and malonates
06/26/2003US20030120071 Chemical compounds
06/26/2003US20030120038 Inhibitor of vascular endothelial cell growth factor
06/26/2003US20030119914 Bis(thio-hydrazide amide) compounds; anticancer agents
06/26/2003US20030119891 Polylactam oligomers of N-methyl-2-carboxy-4-imidazole, N-methyl-2-carboxy-4-aminopyrrole modified by 4-aminobutyric acid, 3-amino-propionic acid and 3-(dimethylamino)propylamine binding specifically to the cyclogenase 2 gene
06/26/2003US20030119885 1,2-Diaminocyclopentanes, e.g., N-(2-(3-(4-chlorophenyl)-propylamino)cyclopentyl)-2-(5-(3,4 -dimethoxyphenyl)pyrimidin-2-ylsulfanyl)acetamide; inhibit eosinphil recruitment; skindisorders; asthma; antiinflammatory agents, antiallergens
06/26/2003US20030119878 A 1-arylalkyl-3-aminoalkyl-1,4-dihydropyrid-4-one derivative; sexual disorders; anticarcinogenic agents; benign prostatic hypertrophy/fibroids of the uterus; endometriosis, polycystic ovarian disease, precocious puberty; contraceptives
06/26/2003US20030119877 Pyridine derivatives useful as cyclooxygenase inhibitor
06/26/2003US20030119874 Method for enhancing mutant enzyme activity in gaucher disease
06/26/2003US20030119869 1-(Piperidin-4-yl)benzimidazole or -triazole derivatives; agonists and antagonist for beta-chemokine (chemotactic cytokines) receptors; viricides; HIV; antiarthritic agents; atherosclerosis, psoriasis, antiallergens; multiple sclerosis
06/26/2003US20030119868 Gyrase inhibitors and uses thereof
06/26/2003US20030119859 Useful in the prophylaxis and treatment of respiratory diseases
06/26/2003US20030119858 Conformationally constrained compounds as pharmaceutical agents
06/26/2003US20030119856 Thiazole compounds useful as inhibitors of protein kinase
06/26/2003US20030119854 Compounds and methods for modulating CXCR3 function
06/26/2003US20030119853 Thiocarboxamide derivatives
06/26/2003US20030119851 In the treatment or prevention of psychotic disorders such as schizophrenia psychotic depression, mania and other central nervous system diseases
06/26/2003US20030119849 Piperazine and piperidine compounds
06/26/2003US20030119847 Heteroaryl derivatives as superior ligands for nociceptin receptor ORL-1
06/26/2003US20030119845 4-((4-benzyl(or methyl heteroaryl)-,1-piperazinyl)(8-quinolinyl)methyl)-N,N-diethylbenzamide or salt, useful for pain treatment
06/26/2003US20030119844 Bind with high selectivity and/ or high affinity to CRF1 receptors (Corticotropin Releasing Factor 1 Receptors), useful for treating psychiatric and neurological diseases, including depression, anxiety and post trauma stress
06/26/2003US20030119840 4-Heteroparyl-1,4-diazabicyclo[3.2.2]nonane, preparation and therapeutic use thereof
06/26/2003US20030119839 Indalones and other fused heterocylce-ones
06/26/2003US20030119838 Water-soluble phenylpyridazine compounds and compositions containing the same
06/26/2003US20030119836 Cyclooxygenase inhibitors
06/26/2003US20030119835 Sulfonyl heteroaryl triazoles as anti-inflammatory/analgesic agents
06/26/2003US20030119834 Angiogenesis inhibitors; 3-alkyl-4-one quinazoline derivatives
06/26/2003US20030119830 Monocyte chemoattractant protein-1 inhibitor compounds
1 ... 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 ... 1564